TNF-α inhibitors (anti-TNF-α) are agents increasingly used in the treatment of rheumatic diseases resistant to classical disease-modifying treatment and they provide significant improvement of disease activity. However, these agents have many cutaneous side effects including psoriasis. Numerous reports of the induction or worsening of psoriasis in patients treated with TNF antagonists indicate that this is not a rare phenomenon. In this study, we present a patient with ankylosing spondylitis who developed palmoplantar pustular psoriasis after receiving anti-TNF-α therapy for 4 months.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/imt.15.45 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Efficacy and Safety of Non-Biologic and Biologic Treatments in Palmoplantar Pustular Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis.
Australas J Dermatol
January 2025
King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.
Palmoplantar pustular psoriasis (PPPP), or palmoplantar pustulosis (PPP), is a type of psoriasis that affects the skin on the palms and soles. It is characterised by dermatosis and small sterile pustules and is considered a significant burden on patients' quality of life, as there is currently no gold standard treatment or cure. This network meta-analysis (NMA) compares the efficacy and safety of biologic and non-biologic medications for PPPP and PPP.
View Article and Find Full Text PDFEfficacy and safety of guselkumab in European patients with palmoplantar pustulosis: A multi-center, single-arm clinical trial (GAP study).
JAAD Int
February 2025
Department of Dermatology, University Medical Center Göttingen, Göttingen, Germany.
Article Synopsis
- - Palmoplantar pustulosis (PPP) is a painful chronic skin disorder affecting the palms and soles, with no approved treatments in Europe and the USA, although guselkumab is approved in Japan.
- - A phase II study involving 50 Caucasian patients showed that administering 100 mg of guselkumab subcutaneously for 24 weeks significantly reduced the severity of PPP, with a median improvement of 59.6% in the PPP severity index.
- - The study concluded that guselkumab could be a viable treatment option for Caucasian patients suffering from moderate-to-severe PPP, as indicated by substantial improvements in both clinical and quality of life measures.
A systematic review of recent randomized controlled trials for palmoplantar pustulosis.
J Dermatolog Treat
December 2024
Division of Dermatology, McMaster University, Hamilton, Canada.
Article Synopsis
- Palmoplantar pustulosis (PPP) is a chronic skin condition that affects the palms and soles, severely impacting patients' daily lives and overall quality of life.
- Recent studies have explored various treatment options, including phototherapy, systemic therapies, and biologics, revealing promising efficacy and safety in newer medications and therapies.
- While treatments like excimer laser and specific biologics showed significant improvement in symptoms, more extensive research is necessary to establish the best long-term treatment strategies for managing PPP.
2023 guidelines on the management of psoriasis by the Dermatological Society of Singapore.
Ann Acad Med Singap
September 2024
Dr SN Wong Skin, Hair, Nails & Laser Specialist Clinic, Singapore.
Article Synopsis
- Psoriasis is a chronic inflammatory skin disease that requires varied management approaches, which the study aimed to standardize through new guidelines tailored for dermatology practice in Singapore.
- A specialized workgroup conducted a comprehensive literature review on psoriasis treatments from 2013 to 2023, refining clinical questions to create practical guidelines covering assessment and management strategies for different severity levels of psoriasis.
- The resulting guidelines suggest various therapies, including both systemic and topical treatments, while addressing specific concerns for special populations and providing recommendations for managing related conditions like psoriatic arthritis.
Spesolimab, the first-in-class anti-IL-36R antibody: From bench to clinic.
J Dermatol
November 2024
Division of Cutaneous Science, Department of Dermatology, Nihon University School of Medicine, Tokyo, Japan.
Article Synopsis
- Inflammatory diseases linked to pro-inflammatory cytokines have led to targeted therapies, with IL-36 cytokines being significant in conditions like generalized pustular psoriasis (GPP) and others.
- The IL-36R-targeting antibody spesolimab shows promise, effectively inhibiting IL-36R signaling and presenting a favorable safety profile in multiple studies.
- Clinical trials highlight spesolimab's ability to improve symptoms and quality of life for GPP patients, while ongoing research continues to explore its efficacy in other related diseases like palmoplantar pustulosis and Netherton syndrome.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!